Current and future: targeted therapy for RUNX1-mutated acute myeloid leukemia

Zhaoyang Jiang

doi:10.1117/12.3012848

8 January 2024 Current and future: targeted therapy for RUNX1-mutated acute myeloid leukemia

Zhaoyang Jiang

Proceedings Volume 12924, Third International Conference on Biological Engineering and Medical Science (ICBioMed2023); 129242J (2024) https://doi.org/10.1117/12.3012848
Event: 3rd International Conference on Biological Engineering and Medical Science (ICBioMed2023), 2023, ONLINE, United Kingdom

Abstract

Acute myeloid leukemia (AML) is a stubborn malignant tumor, and AML with different mutations often exhibits significant heterogeneity, which poses challenges to the treatment of AML. RUNX1 is a vital transcription component participated in regulation of blood tissue development, and mutated RUNX1 are common in AML and are one of the typical mutations. Clinical studies have demonstrated that AML patients with mutated RUNX1 often have poor prognosis and lower survival rates, and have a worsening trend of bone marrow hyperplasia. Based on such patients, there is an urgent need for a more efficient treatment strategy that targets RUNX1 or its related factors to alleviate the adverse effects of RUNX1 mutations on AML patients. This article systematically examines RUNX1's function in the pathophysiology and prognosis of AML. From the perspective of the mechanism and patients, the impact of RUNX1 on AML and the relevant targeted treatment strategies currently being promoted are summarized and discussed. This article is dedicated to summarize the development direction and trends of current RUNX1 related AML treatment strategies, and deepen people's understanding of RUNX1-mutated AML.

(2024) Published by SPIE. Downloading of the abstract is permitted for personal use only.

Citation Download Citation

Zhaoyang Jiang "Current and future: targeted therapy for RUNX1-mutated acute myeloid leukemia", Proc. SPIE 12924, Third International Conference on Biological Engineering and Medical Science (ICBioMed2023), 129242J (8 January 2024); https://doi.org/10.1117/12.3012848

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available

Members: $17.00

Non-members: $21.00 ADD TO CART

PROCEEDINGS
6 PAGES

DOWNLOAD PAPER SAVE TO MY LIBRARY

GET CITATION

RIGHTS & PERMISSIONS

Get copyright permission Get copyright permission on Copyright Marketplace

KEYWORDS

Leukemia

In vitro testing

Tissues

Blood

Bone

Proteins

Tumors

Show All Keywords

Keywords/Phrases

Search In:

Publication Years